Slo-Niacin.com Gets at the Heart of Cholesterol Management
MAPLE GROVE, Minn., July 12 /PRNewswire/ — Upsher-Smith Laboratories, Inc., the maker of Slo-NiacinÃ‚®, announced today the launch of a new website as part of an ongoing dedication to providing the latest in heart health at the click of a mouse. Slo-Niacin.com provides a wealth of credible information about cholesterol management. The site educates visitors about heart disease and includes “Cholesterol Basics,” a guide to interpreting cholesterol levels and facts about common heart disease risk factors. The website also reviews recommendations on how to optimize cholesterol management along with tips to leading a healthy lifestyle, including fitness, nutrition and how the integration of a supplement containing nicotinic acid, like Slo-NiacinÃ‚®, can support overall heart health.
“We know how important it is to be informed when it comes to managing overall heart health,” said Tina Fehr, product manager for Slo-NiacinÃ‚®. “The new website gives visitors easy access to credible information about cholesterol management, along with an improved store locator for the ultimate convenience on where to buy Slo-NiacinÃ‚® and how to obtain valuable coupons.”
Slo-NiacinÃ‚® is a nonprescription dietary niacin supplement containing nicotinic acid, the most effective substance available for increasing high-density lipoprotein (HDL), “good cholesterol”. Niacin is a B vitamin that aids in the function of the digestive system, skin and nerves. Slo-NiacinÃ‚® has been shown in clinical studies to support heart health and good cholesterol (HDL) when used under the care and monitoring of a healthcare professional. Slo-NiacinÃ‚® is effective alone or as a complement to statins.
About Slo-NiacinÃ‚® Tablets
Slo-NiacinÃ‚® Tablets utilize a patented polygelÃ‚® controlled-release delivery system that gradually deliver niacin into the body. They are designed to reduce the incidence of flushing and itching commonly associated with immediate-release niacin use. Slo-NiacinÃ‚® Tablets are economical and often cost less than an insurance co-payment, at approximately $16 per month for one hundred 500 mg tablets. Three dosage strengths (250 mg, 500 mg, and 750 mg) of Slo-NiacinÃ‚® Tablets are available to meet the specific goals patients set with their healthcare providers.
Slo-NiacinÃ‚® Tablets are manufactured by Upsher-Smith Laboratories, Inc., a trusted manufacturer of high quality prescription and dietary supplement products, and are conveniently available at pharmacies and other retailers nationwide. To purchase online or to find a retailer near you, visit www.slo-niacin.com/store-locator.
About Upsher-Smith Laboratories, Inc.
Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Over the last 20 years that Upsher-Smith has been manufacturing Slo-NiacinÃ‚®, more than 10 million bottles have been sold. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Important Safety Information
Read the information leaflet provided with each bottle of Slo-NiacinÃ‚® Tablets.
Do not use Slo-NiacinÃ‚® Tablets if you have a known sensitivity or allergy to niacin. Do not take niacin unless under your healthcare provider’s supervision if you have heart disease (particularly, recurrent chest pain or recent heart attack), gallbladder disease, gout, arterial bleeding, glaucoma, diabetes, impaired liver function, stomach ulcers, or are pregnant or lactating. Before taking more than 500 mg/day, call your healthcare provider. If you are taking high blood pressure or cholesterol-lowering drugs, call your healthcare provider before taking niacin due to possible interactions. Case reports of unexplained muscle-related complaints, including discomfort, weakness, or tenderness, have been documented with HMG-CoA Reductase Inhibitors in combination with niacin. Increased uric acid, glucose, and abnormal liver function tests have been reported in persons taking 500 mg/day or more. Discontinue use and call your healthcare provider immediately if you experience persistent flu-like symptoms (nausea, vomiting, not feeling well), loss of appetite, decreased and dark-colored urine, muscle discomfort or weakness, irregular heartbeat or vision problems. Niacin may cause temporary flushing, itching and tingling, feelings of warmth and headache, particularly when beginning, increasing dosage or changing brands. This safety information is not all-inclusive. For more information, contact your healthcare provider, call 1-800-654-2299, or visit www.slo-niacin.com.
Sources: Mayo Clinic. http://www.mayoclinic.com/health/niacin/cl00036. April 13, 2009. Lavie CJ, Mailander L, Milani. "Marked benefit with sustained- release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease." Am J Cardiol. 1992;69:1083-1085. Squires RW, Allison TG, Gau GT, et al. "Low-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol." Mayo Clin Proc. 67:855- 860, 1992. Gray DR, Morgan T, Chretien SD, Kashyap ML. "Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans." Ann Intern Med. 1994;121:252-258. Knopp RF, Retzlaff BM, Fish B et al. "The SLIM study: Slo-Niacin(R) and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia." Journal of Clinical Lipidology, Volume 3, Issue 3, Pages 167-178. Slo-Niacin product information. http://www.slo-niacin.com/about- slo-niacin/directions-for-use. Upsher-Smith Laboratories, Inc., 2010. Drugstore.com website. http://www.drugstore.com. Accessed February 10, 2010.
SOURCE Upsher-Smith Laboratories, Inc.